Robert J Scarborough

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6092005/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Efficacy, accumulation, and transcriptional profile of anti-HIV shRNAs expressed from human U6, 7SK, and H1 promoters. Molecular Therapy - Nucleic Acids, 2021, 23, 1020-1034.	2.3	10
2	Cloning and Detection of Aptamer-Ribozyme Conjugations. Methods in Molecular Biology, 2021, 2167, 253-267.	0.4	3
3	Small RNAs to treat human immunodeficiency virus type 1 infection by gene therapy. Current Opinion in Virology, 2019, 38, 10-20.	2.6	11
4	A U1i RNA that Enhances HIV-1 RNA Splicing with an Elongated Recognition Domain Is an Optimal Candidate for Combination HIV-1 Gene Therapy. Molecular Therapy - Nucleic Acids, 2019, 18, 815-830.	2.3	9
5	[A second patient cured of HIV infection: hopes and limitations]. Virologie, 2019, 23, 1-4.	0.1	4
6	RNA Interference Therapies for an HIV-1 Functional Cure. Viruses, 2018, 10, 8.	1.5	36
7	Higher Cytopathic Effects of a Zika Virus Brazilian Isolate from Bahia Compared to a Canadian-Imported Thai Strain. Viruses, 2018, 10, 53.	1.5	29
8	Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy. Journal of Visualized Experiments, 2016, , .	0.2	3
9	592. A Comparison of Length on the Potency and Toxicity of Small Interfering and Short Hairpin RNAs Targeting a Highly Conserved Site in HIV-1 RNA Coding for the Gag Polyprotein. Molecular Therapy, 2015, 23, S235-S236.	3.7	0
10	HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs. RNA Biology, 2015, 12, 123-135.	1.5	14
11	HIV and Ribozymes. Advances in Experimental Medicine and Biology, 2015, 848, 97-116.	0.8	25
12	Effective Inhibition of HIV-1 Production by Short Hairpin RNAs and Small Interfering RNAs Targeting a Highly Conserved Site in HIV-1 Gag RNA Is Optimized by Evaluating Alternative Length Formats. Antimicrobial Agents and Chemotherapy, 2015, 59, 5297-5305.	1.4	13
13	A Conserved Target Site in HIV-1 Gag RNA is Accessible to Inhibition by Both an HDV Ribozyme and a Short Hairpin RNA. Molecular Therapy - Nucleic Acids, 2014, 3, e178.	2.3	16
14	Design and Evaluation of Clinically Relevant SOFA-HDV Ribozymes Targeting HIV RNA. Methods in Molecular Biology, 2014, 1103, 31-43.	0.4	14
15	In vitro and in vivo cleavage of HIV-1 RNA by new SOFA-HDV ribozymes and their potential to inhibit viral replication. RNA Biology, 2011, 8, 343-353.	1.5	17
16	A Pharmacokinetic Study of Plerixafor in Subjects with Varying Degrees of Renal Impairment. Biology of Blood and Marrow Transplantation, 2010, 16, 95-101.	2.0	32
17	Pharmacology of AMD3465: A small molecule antagonist of the chemokine receptor CXCR4. Biochemical Pharmacology, 2009, 78, 993-1000.	2.0	50
18	Characterization of the TRBP domain required for Dicer interaction and function in RNA interference. BMC Molecular Biology, 2009, 10, 38.	3.0	117

#	Article	IF	CITATIONS
19	Inhibition of HIV-1 expression and replication by SOFA-HDV ribozymes against Tat and Rev mRNA sequences. Retrovirology, 2009, 6, .	0.9	0
20	Pharmacokinetic Effect of AMD070, an Oral CXCR4 Antagonist, on CYP3A4 and CYP2D6 Substrates Midazolam and Dextromethorphan in Healthy Volunteers. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 559-565.	0.9	19